Mylan - Now a Part of Viatris
WEBMylan is now part of Viatris, a new global healthcare company committed to empowering people to live healthier at every stage of life. We encourage you to learn more about our commitment to increasing access to quality medicines for …
Mylan and Pfizer Announce Viatris as the New Company Name in …
WEBNov 12, 2019 — Customers and patients will continue to be served by the Mylan and Upjohn brands for the near future. The new name will be effective upon closing of the combination, which is expected to occur in mid-2020. The two companies will continue to operate as independent, separate organizations until close.
Mylan Investor Relations | Mylan N.V.
WEBMylan Announces Third Quarter 2020 Financial Results and Looks Ahead to the Launch of Viatris Inc. Nov 02, 2020. Mylan Announces Appointment of Experienced Pharmaceutical Executive Bill Szablewski as Head of Capital Markets for Viatris. Oct 30, 2020.
Mylan and Biocon Announce U.S. FDA Approval of Semglee™ …
WEBJun 11, 2020 — Mylan and Biocon Biologic's insulin glargine has received regulatory approval in more than 45 countries around the world and is the third product approved by FDA through the Mylan-Biocon Biologics collaboration.
Mylan to Acquire Meda | Mylan N.V.
WEBFeb 10, 2016 — Mylan N.V. (NASDAQ, TASE: MYL), a leading global pharmaceutical company ("Mylan"), today announced a recommended public offer to the shareholders of Meda Aktiebolag (publ.) ("Meda") to tender all their shares in Meda to Mylan (the "Offer").
Mylan Announces Worldwide Collaboration with Momenta to …
WEBJan 8, 2016 — Under the agreement with Momenta, Mylan will make an up-front cash payment of $45 million and up to $200 million in contingent milestone-related payments to Momenta, with each company sharing equally in the costs and profits with respect to …
Mylan Completes Acquisition of Certain Businesses from Famy …
WEBNov 20, 2015 — The transaction brings Mylan a broad women's care portfolio, strong technical capabilities and dedicated hormone manufacturing, which, when combined with Mylan's expansive global commercial footprint and supply chain infrastructure, will create a leading women's healthcare franchise.
Mylan Laboratories Completes Matrix Laboratories Transaction
WEBIn light of the previously- announced closing of the acquisition of 20% of Matrix's outstanding shares under an open offer to Matrix shareholders, MP Laboratories (Mauritius) Ltd, a wholly-owned subsidiary of Mylan, now owns approximately 71.5% of the voting share capital of Matrix.
Mylan Raises Offer to Acquire Perrigo | Mylan N.V.
WEBApr 8, 2015 — As a result of the Increased Offer, it is expected that, following the consummation of the transaction, Mylan shareholders will own approximately 60.7% of the outstanding Mylan ordinary shares on a fully diluted basis and former Perrigo shareholders will own approximately 39.3% of the outstanding Mylan ordinary shares on a …
Mylan Relocates Corporate Headquarters | Mylan N.V.
WEBApr 10, 2003 — Vice Chairman and CEO, Robert J. Coury stated, "Our relocation to Southpointe brings Mylan's Corporate Headquarters substantially closer to our main operating and development facility, as well as to our largest employee base.
- Some results have been removed